Over the last eighteen months our team has worked with polymer contracting experts to optimize our hydrogel component. Our objectives were to maximize production output, to refine our specifications to yield the optimum gelation and resorption characteristics, to demonstrate reproducibility and to ensure that any residual solvents were minor and well below the FDA specifications limits for human therapy. As part of our improved Quality Management System, we are confident that the new Vivos Inc Standard Operating Procedure for Polymer Production will meet GMP/FDA Specifications.
Dr.
“This filing was on the heels of another milestone for Vivos, as the US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, US Patent Application Serial No: 16-459,466. Our new particle patent and our hydrogel component patent filing are significant achievements consistent with our objective for strong intellectual property protection on both of our key components. We will continue to improve our processes to enhance our intellectual property as a fundamental business strategy as we continue our progress in establishing Radiogel™ and Isopet® as a next generation treatment option using Injectable Precision Radionuclide Therapy.”
About
Radiogel™ is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
Radiogel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
The Isopet® Solutions division is used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the
In 2018 the Company obtained confirmation from the
Isopet® for treating animals uses the same technology as RadioGel™ for treating humans. The
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
President & CEO
MKorenko@RadioGel.com
Source:
2022 GlobeNewswire, Inc., source